• Procedure started
  • Under evaluation
  • PRAC recommendation
  • CHMP opinion
  • European Commission final decision
Current status:
European Commission final decision


EMA review of Zinbryta confirms medicine's risks outweigh its benefits

Multiple sclerosis medicine no longer authorised and has been recalled from hospitals and pharmacies

EMA's Pharmacovigilance Risk Assessment Committee (PRAC) has confirmed that the multiple sclerosis medicine Zinbryta (daclizumab beta) poses a risk of serious and potentially fatal immune reactions affecting the brain, liver and other organs.

Patients could be at risk from the start of treatment and for several months after stopping treatment, and it is not possible to predict which patients will be affected. The PRAC therefore confirmed its previous conclusions that risks of Zinbryta outweigh its benefits for patients with multiple sclerosis.

Healthcare professionals should continue monitoring patients who have been treated with Zinbryta in line with recommendations issued in PDF iconMarch 2018 .

There are no immediate consequences of the PRAC's review as Zinbryta is no longer authorised in the EU. On 27 March 2018, the marketing authorisation was withdrawn at the request of Biogen Idec Ltd, the company that marketed the medicine. Zinbryta is no longer available in hospitals and pharmacies in the EU.

A full assessment report on the review will be published shortly.

Key facts

About this medicine
Approved name
International non-proprietary name (INN) or common name


Associated names
About this procedure
Current status
European Commission final decision
Reference number
Article 20 procedures

This type of procedure is triggered for medicines that have been authorised via the centralised procedure in case of quality, safety or efficacy issues.

Decision making model
Authorisation model
Centrally authorised product(s)
Key dates and outcomes
Procedure start date
PRAC recommendation date
EC decision date

All documents

Procedure started

Under evaluation

  • List item

    Zinbryta Article-20 procedure - Scientific conclusions (PDF/49.53 KB)

    First published: 14/03/2018
    Last updated: 14/03/2018

  • List item

    Zinbryta Article-20 procedure - Assessment report on provisional measures (PDF/169.92 KB)

    First published: 14/03/2018
    Last updated: 14/03/2018

  • List item

    Zinbryta Article-20 procedure - Multiple sclerosis medicine Zinbryta suspended in the EU (PDF/86.41 KB)

    First published: 07/03/2018
    Last updated: 14/03/2018

  • Recommendation provided by Pharmacovigilance Risk Assessment Committee

  • List item

    Zinbryta Article-20 procedure - EMA review of Zinbryta confirms medicine’s risks outweigh its benefits (PDF/74.71 KB)

    First published: 18/05/2018
    Last updated: 11/07/2018

  • European Commission final decision

    Document description

    • Annex I - List of the medicines affected by the referral
    • Annex II - Scientific conclusions of the CHMP or CMDh
    • Annex III - Changes to the summary of product characteristics, labelling or package leaflet - available when the CHMP or CMDh recommends changes to the product information. Also includes conditions for lifting of suspensions, if applicable
    • Annex IV - Conditions of the marketing authorisation - available when the CHMP or CMDh recommends other measures to be taken for the marketing authorisation such as safety measures or additional studies
    • Notification - A letter from a Member State, the European Commission or a marketing-authorisation holder requesting the initiation of a referral procedure
    • Rationale for triggering - Background provided by the party triggering the referral explaining the issues leading to the initiation of the procedure
    • PRAC list of questions - Questions agreed by the PRAC requesting further information to evaluate the issues identified
    • PRAC timetable - Timeframe agreed by the PRAC to receive information, assess the issues and adopt a recommendation
    • PRAC / CHMP or CMDh assessment report - The assessment and conclusions of the PRAC and CHMP or CMDh on the issues investigated


    How useful was this page?

    Add your rating